Mackay I R, Goodyear M D, Riglar C, Penschow J
Cancer Immunol Immunother. 1983;16(2):98-100. doi: 10.1007/BF00199239.
Natural killer (NK) cell activity and antibody-dependent (K) cell activity were studied sequentially in 30 patients with early node-positive breast cancer entered into an adjuvant chemotherapy trial. The drugs used were melphalan, and melphalan with methotrexate, given for 12 months. Estimations were made 3-monthly during chemotherapy, and then at 15 and 24 months to assess recovery. Mean values for NK-cell activity during chemotherapy were significantly lower than the mean pre-chemotherapy baseline value at all time-points from 3 to 15 months, but there was recovery by 24 months. Mean values for K-cell activity during chemotherapy did not appear to differ from the mean pre-chemotherapy value, but variability in individual values was high. Over a 4-year follow-up period, a comparison of 16 patients who did not develop recurrent breast cancer with 14 who did showed that NK-cell activity was significantly lower in the latter group 12 months after the start of chemotherapy.
对30例早期淋巴结阳性乳腺癌患者进行辅助化疗试验，依次研究了自然杀伤（NK）细胞活性和抗体依赖性（K）细胞活性。所用药物为美法仑，以及美法仑与甲氨蝶呤联合用药，疗程为12个月。化疗期间每3个月进行一次评估，然后在15个月和24个月时评估恢复情况。化疗期间NK细胞活性的平均值在3至15个月的所有时间点均显著低于化疗前的平均基线值，但在24个月时有所恢复。化疗期间K细胞活性的平均值似乎与化疗前的值没有差异，但个体值的变异性较高。在4年的随访期内，对16例未发生复发性乳腺癌的患者与14例发生复发性乳腺癌的患者进行比较，结果显示化疗开始后12个月，后一组患者的NK细胞活性显著较低。
